4-Methyl-2-[3-[1-(2-methylprop-2-enyl)pyrrolidin-1-ium-1-yl]-1-phenylpropyl]phenol;bromide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-Methyl-2-[3-[1-(2-methylprop-2-enyl)pyrrolidin-1-ium-1-yl]-1-phenylpropyl]phenol;bromide
• 化学式: C24H32BrNO
• 分子量: 430.4
• InChiKey: LQALXWLZAQIGDA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.41
• 重原子数：
  27
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Combination therapies
  申请人：Pfizer Inc

  公开号：US20040209916A1

  公开（公告）日：2004-10-21

  The invention is directed to methods of treating asthma, COPD, allergic rhinitis, and infectious rhinitis by administering a first pharmaceutical agent including one or more compounds selected from the quarternary ammonium compounds of formulae I-V and a second pharmaceutical agent including one or more pharmaceutical agents selected from Adenosine A 2a Receptor Agonists, D2-Dopamine Receptor Agonists, Phosphodiesterase Inhibitors (PDE's), corticosteroids, norepinephrine reuptake inhibitors, 4-hydroxy-7-[2-[2-[3-[2-phenylethoxy]-propylsulphonyl]ethylamino]ethyl]-1,3-benzothiazol-2(3H)-one, and pharmaceutically acceptable salts thereof, and non-quarternized antimuscarinic compounds.

  该发明涉及通过给予包括公式I-V的季铵化合物中选取的一个或多个化合物以及包括选自腺苷A2a受体激动剂、D2-多巴胺受体激动剂、磷酸二酯酶抑制剂（PDE's）、皮质类固醇、去甲肾上腺素再摄取抑制剂、4-羟基-7-[2-[2-[3-[2-苯乙氧基]-丙磺酰乙氨基]-乙基]-1,3-苯并噻唑-2(3H)-酮及其药用可接受的盐以及非季铵化的抗胆碱药物的第二药物，来治疗哮喘、COPD、过敏性鼻炎和感染性鼻炎的方法。
• [EN] QUATERNARY AMMONIUM COMPOUNDS AND THEIR USE AS ANTIMUSCARINIC AGENTS<br/>[FR] COMPOSES D'AMMONIUM QUATERNAIRE ET LEUR UTILISATION COMME AGENTS ANTIMUSCARINIQUES
  申请人：UPJOHN CO

  公开号：WO2004091607A1

  公开（公告）日：2004-10-28

  Novel quaternary ammonium compounds of the formula and any stereoisomers thereof, wherein R1, R2 R3, R4, R5, R6, R7, and X- are defined herein. The compounds are useful as medicaments for treatment of treatment of asthma, a group of breathing disorders termed Chronic Obstructive Pulmonary Disease (COPD), allergic rhinitis, rhinorrhea due to the common cold, and urinary disorder.

  该化合物的新型季铵盐化合物及其任何立体异构体，其中R1、R2、R3、R4、R5、R6、R7和X-在此定义。该化合物可用作治疗哮喘、慢性阻塞性肺疾病（COPD）呼吸障碍、过敏性鼻炎、普通感冒引起的鼻涕和尿路障碍的药物。
• Method of treating irritable bowel syndrome
  申请人：Pfizer Inc

  公开号：US20040220224A1

  公开（公告）日：2004-11-04

  The invention features a method of treating irritable bowel syndrome (IBS) by administering quarternary ammonium compounds of formulae I-V, described herein.

  该发明涉及一种通过给予公式I-V所述的季铵化合物来治疗肠易激综合症(IBS)的方法。
• Quatemary ammonium compounds
  申请人：Pfizer Inc.

  公开号：US20040242569A1

  公开（公告）日：2004-12-02

  Novel quaternary ammonium compounds of the formula 1 and any stereoisomers thereof, wherein R 1 , R 2 R 3 , R 4 , R 5 , R 6 , R 7 , and X − are defined herein. The compounds are useful as medicaments for treatment of treatment of asthma, a group of breathing disorders termed Chronic Obstructive Pulmonary Disease (COPD), allergic rhinitis, rhinorrhea due to the common cold, and urinary disorder.

  本发明涉及式1及其任何立体异构体的新型季铵化合物，其中R1、R2、R3、R4、R5、R6、R7和X-如本文所定义。该化合物可用作治疗哮喘、慢性阻塞性肺疾病（COPD）等一组呼吸障碍、过敏性鼻炎、因普通感冒引起的流涕以及泌尿障碍的药物。
• COMBINATION THERAPIES
  申请人：Pharmacia & Upjohn Company LLC

  公开号：EP1620083A2

  公开（公告）日：2006-02-01